Please login to the form below

Not currently logged in
Email:
Password:

Adaptimmune appoints Lawrence Alleva to its board

The former PwC partner will also chair its boardaudit committee

Adaptimmune Lawrence Larry Alleva Adaptimmune has appointed former PwC partner Lawrence (Larry) Alleva to its board of directors as an independent, non-executive director.

Alleva will also serve as chairman of the Oxford, UK-based clinical-stage biotechnology company's board audit committee.

Commenting on his new role he said: “I am very pleased to be joining Adaptimmune at this interesting time, and I look forward to working closely with the team as we aim to build the company up with the expansion of its UK and US operations.”

Alleva spent 39 years with PricewaterhouseCoopers (PwC), until his retirement in 2010, and served in a variety of office, regional and national practice leadership roles, most recently as the US ethics and compliance leader for the firm's Assurance Practice from 2006.

He currently serves as a director for public companies Tesaro and Bright Horizons Family Solutions, and for the privately-held Mirna Therapeutics, and chairs those companies' audit committees.

Dr Jonathan Knowles, chairman of Adaptimmune, said: “I am delighted that such a high caliber individual as Larry Alleva has agreed to join our board of directors.

"His substantial corporate finance and accounting expertise, combined with his extensive experience of supporting growing biotech firms, brings significant added value to the company, and complements the skills and experience of our other board members.”

Alleva's appointment follows a brace of recent senior hires that saw Adaptimmune recruit a new chief medical officer and chief financial officer.

11th March 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....